Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase III for Persistent Corneal Epithelial Defects. According to GlobalData, Phase III drugs for Persistent Corneal Epithelial Defects does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lufepirsen LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lufepirsen overview

Lufepirsen is under development for the treatment of persistent corneal epithelial defects which are secondary to trauma and refractory to standard of care. The drug candidate is applied as an ophthalmic gel. The drug candidate binds to connexin 43. CODA-001 is a natural, unmodified antisense oligonucleotide. It was also under development for the treatment of venous leg ulcer, diabetic foot ulcers, skin wounds, and near sightedness after PRK laser eye surgery.

Amber Ophthalmics overview

Amber Ophthalmics is a biopharmaceutical company that discovers and develops ocular drugs. It is investigating its lead product candidate NEXAGON (lufepirsen), an oligonucleotide-based drug for the treatment of PED CTI (persistent epithelial defects due to thermal and chemical injuries) and ocular surface indications. The company’s product candidate inhibits a cell membrane hemichannel forming protein, connexin43 (Cx43) that is overexpressed after acute injury and chronic disease states. Its drug focuses on re-establishing limbal microvasculature and regenerating the corneal epithelium. Amber Ophthalmics is headquartered in San Diego, California, the US.

For a complete picture of Lufepirsen’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.